Copyright
©The Author(s) 2023.
World J Gastroenterol. Jun 28, 2023; 29(24): 3871-3882
Published online Jun 28, 2023. doi: 10.3748/wjg.v29.i24.3871
Published online Jun 28, 2023. doi: 10.3748/wjg.v29.i24.3871
Table 2 Summary of radiographic response per response evaluation criteria in solid tumors version 1.1
| Variable | n = 25 |
| Best overall response, n (%) | |
| Complete response | 17 (68) |
| Partial response | 7 (28) |
| Stable disease | 0 |
| Progressive disease | 1 (4) |
| Objective response rate, n (%) | 24 (96) |
| Disease control rate, n (%) | 24 (96) |
| 1 yr local control rate, n (%) | 25 (100) |
- Citation: Chen YX, Yang P, Du SS, Zhuang Y, Huang C, Hu Y, Zhu WC, Yu YY, Liu TS, Zeng ZC. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial. World J Gastroenterol 2023; 29(24): 3871-3882
- URL: https://www.wjgnet.com/1007-9327/full/v29/i24/3871.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i24.3871